Efficacy of sodium oxybate plus disulfiram for the maintenance of alcohol abstinence in treatment-resistant patients with alcohol use disorder: a multicentre retrospective study.
Fabio Caputo, Caterina Trevisan, Teo Vignoli, Angelo Giovanni Icro Maremmani, Franco Montesano, Gianfranco Carboni, Lisa Lungaro, Anna Costanzini, Giacomo Caio, Gianni Testino, Stefano Volpato, Roberto De Giorgio
{"title":"Efficacy of sodium oxybate plus disulfiram for the maintenance of alcohol abstinence in treatment-resistant patients with alcohol use disorder: a multicentre retrospective study.","authors":"Fabio Caputo, Caterina Trevisan, Teo Vignoli, Angelo Giovanni Icro Maremmani, Franco Montesano, Gianfranco Carboni, Lisa Lungaro, Anna Costanzini, Giacomo Caio, Gianni Testino, Stefano Volpato, Roberto De Giorgio","doi":"10.4415/ANN_24_04_03","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Disulfiram (DF), acamprosate, naltrexone, baclofen and sodium oxybate (SO) are currently the medications approved for the treatment of alcohol use disorder (AUD). In this context, combined pharmacological interventions and sex differences are an interesting area in the treatment of non-responder AUD patients.</p><p><strong>Aim: </strong>To evaluate the efficacy of SO in combination with DF in maintaining alcohol abstinence in patients with AUD who failed to achieve abstinence either with SO or DF alone.</p><p><strong>Methods and results: </strong>126 detoxified AUD patients, previously treated with only SO or DF, were retrospectively enrolled from 2018 to 2022. At the end of treatment, a higher number of females than males (74.1% vs 66.3%: p=0.03) maintained continuous abstinence from alcohol, and all the females responded completely or partially to the treatment.</p><p><strong>Conclusions: </strong>This study shows that the combination of SO and DF may be considered a further pharmacological opportunity for AUD patients (particularly in females) who do not respond to mono-therapy.</p>","PeriodicalId":502090,"journal":{"name":"Annali dell'Istituto superiore di sanita","volume":"60 4","pages":"252-257"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annali dell'Istituto superiore di sanita","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4415/ANN_24_04_03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Disulfiram (DF), acamprosate, naltrexone, baclofen and sodium oxybate (SO) are currently the medications approved for the treatment of alcohol use disorder (AUD). In this context, combined pharmacological interventions and sex differences are an interesting area in the treatment of non-responder AUD patients.
Aim: To evaluate the efficacy of SO in combination with DF in maintaining alcohol abstinence in patients with AUD who failed to achieve abstinence either with SO or DF alone.
Methods and results: 126 detoxified AUD patients, previously treated with only SO or DF, were retrospectively enrolled from 2018 to 2022. At the end of treatment, a higher number of females than males (74.1% vs 66.3%: p=0.03) maintained continuous abstinence from alcohol, and all the females responded completely or partially to the treatment.
Conclusions: This study shows that the combination of SO and DF may be considered a further pharmacological opportunity for AUD patients (particularly in females) who do not respond to mono-therapy.
简介:双硫仑(DF)、阿坎普罗酸、纳曲酮、巴氯芬和氧化钠(SO)是目前批准用于治疗酒精使用障碍(AUD)的药物。在这种情况下,联合药物干预和性别差异是治疗无反应AUD患者的一个有趣的领域。目的:评价SO联合DF对单用SO或DF均不能戒酒的AUD患者维持酒精戒断的疗效。方法和结果:从2018年到2022年,回顾性纳入126例先前仅接受SO或DF治疗的解毒AUD患者。治疗结束时,女性持续戒酒的人数高于男性(74.1% vs 66.3%: p=0.03),所有女性对治疗均有完全或部分反应。结论:本研究表明,对于单药治疗无效的AUD患者(尤其是女性患者),SO和DF联合用药可能被认为是进一步的药理学机会。